Hemoglobin in Medical Technology

New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring

... including: noninvasive and continuous total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), ... SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), ... and deliver clinical improvement over alternative hemoglobin and fluid assessment measurement capabilities to ...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

... of using intermittent, invasive measurements of hemoglobin to help guide transfusion decisions may ... not simply be based on any particular level of hemoglobin but rather a thorough evaluation of the patient, including whether hemoglobin levels are stable or changing. The ability to ...

Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease

... sufficient to sustain therapeutic elevation of hemoglobin in most patients. The earliest patients to receive treatment have shown sustained hemoglobin within the target range for four months without ... comparable low dose does not result in sufficient hemoglobin levels in most patients. By having ...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

... blood vessels. In sickle cell disease, the hemoglobin carried by the red blood cells is abnormal, ... event. Daytime Steady-State hemoglobin Saturation Is a Determinant of Cerebral Artery ... , TX This study determined that low hemoglobin saturation (a decrease in the amount of oxygen in ...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

... agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ... Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. ... administered ESAs to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ...

Gene Therapy Corrects Sickle Cell Disease in Laboratory Study

... in the blood of an immature fetal form of hemoglobin in red blood cells. This immature hemoglobin, ... hydroxyurea encourages the formation of fetal hemoglobin and alleviates disease symptoms. "While ... use gene transfer to permanently increase fetal hemoglobin levels," said Derek Persons, M.D., Ph.D., ...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

... Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. ... ESAs to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ... trials of patients with cancer. A rate of hemoglobin rise of 1 g/dL over 2 weeks may contribute ...

Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes

... (Hp), a common serum protein, is to bind free hemoglobin released from red blood cells. Extracellular hemoglobin (hemoglobin not found in red blood cells) is ... damage. Haptoglobin binds to this extracellular hemoglobin and inhibits hemoglobin induced oxidation. ...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... improvement in fatigue, (ES: +1.0) when the hemoglobin level increased as compared to anemic cancer ... improvement in fatigue (ES:+0.72) when hemoglobin levels did not improve compared to ... did not change meaningfully (ES:+0.15) when hemoglobin levels did not improve. * Importantly, ...

DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes

... GlycoMark May Be a More Effective Monitor Than hemoglobin A1C of Exenatide, Sitagliptin, Pramlintide and ... after-meal glucose levels, than the gold standard hemoglobin A1C test in moderately controlled patients with ... test (GlycoMark) correlated more strongly than hemoglobin A1C with all self-monitored plasma glucose (SMPG) ...

Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions

... in cancer chemotherapy patients with various hemoglobin (Hb) levels prior to or during administration ... that when patients achieved lower mean hemoglobin levels during ESA therapy for ... agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ...

New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... associations between lower mean baseline hemoglobin (Hb) levels and the rate of blood transfusions, ... Chemotherapy Patients Based on Achieved hemoglobin (Hb) Levels Kay Larholt, Sc.D., Abt Associates, ... chemotherapy-treated oncology patients who had hemoglobin concentrations less than 10 g/dL prior to ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

... hypertension or diabetes, and show the impact on hemoglobin (Hb) control using a software-based management ... both on study outcomes. Data on the Impact on hemoglobin Control Using a Software-Based Management Tool -- Abstract: Use of Epoetin Alfa in Maintaining hemoglobin Control Through a Software-Based Management ...

Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote

... agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ... Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. ... and cervical cancers when dosed to target a hemoglobin of greater than or equal to 12 g/dL. -- The ...

Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia

... patients seen in some studies with high hemoglobin targets; -- Recommend additional research to ... agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ... Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. ...

New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care

... Noninvasive hemoglobin Receives Rave Reviews from Attendees at Masimo's ... the world were able to preview noninvasive total hemoglobin (SpHb(TM)) and oxygen content (SpOC(TM)) as part ... Continuous Noninvasive Measurement of hemoglobin via Pulse CO-Oximetry(1), a clinical study led by ...

Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents

... ESA treatment. In addition, wide variability in hemoglobin levels prior to transfusion was reported. These ... analyses indicate that the presence of a lower hemoglobin when ESA therapy was initiated was associated ... agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in ...

Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood

... differences are significant. The level of hemoglobin (the oxygen-carrying molecule in the blood) ... math, and executive function. Patients with lower hemoglobin scores had lower IQ scores, and ischemic lesions ... of the neuropsychological impairment observed. hemoglobin levels, age, and hippocampal volume were ...

PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting

... greater than or equal to 9 weeks and baseline hemoglobin greater than or equal to 11 and less than or ... intervention with Epoetin alfa when hemoglobin decreased to <11 g/dL. -- Abstract: Erythroid ... with non-myeloid malignancy, baseline hemoglobin greater than or equal to 11 and less than or ...

Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions

... with the use of ESAs "when dosed to target a hemoglobin of >= 12 g/dL" and instructs physicians to "use ... to establish the risk of using ESAs when hemoglobin levels are less than 12 g/dL. The CMS NCD, on the ... to suggest that initiating ESA treatment at a hemoglobin level >10 g/dL significantly reduces the risk of ...

Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)

... (CMS), which denies coverage for ESAs above the hemoglobin levels of 10 gm/dL. US Oncology and its ... NCD policy, Medicare beneficiaries risk reaching hemoglobin levels oncologists regard as inappropriately low ... not been excluded when ESAs are dosed to target a hemoglobin of < 12 gm/dL." While US Oncology agrees with ...

ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients

... anemic as a result of chemotherapy when their hemoglobin approaches or falls below 10 g/dL, as well as ... -- Suggests that when using ESAs, hemoglobin can be raised to (or near) a concentration of ... Dose reductions are also recommended when hemoglobin rise exceeds 1 g/dL in any two-week period or ...

New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting

... intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective ... Exhibit Hall, Moscone Center) -- Stable hemoglobin (Hb) levels are maintained with once-monthly ... -- Once-monthly C.E.R.A. maintains stable hemoglobin (Hb) in patients (pts) with chronic kidney ...

Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients

... the medical community to achieve a consensus on hemoglobin and dosing levels for ... Without ESA therapy, ESRD patients may develop hemoglobin levels that are dangerously low. Before ESAs were ... and non- dialysis CKD patients should target hemoglobin levels in the range of 11 to 12 g/dL. These ...

Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label

... by the FDA Advisory Committees evaluated hemoglobin targets above 13 grams per deciliter of blood ... for all ESAs was revised to reflect a maximum hemoglobin of 12 g/dL. When patients are treated according ... experience the greatest benefit from a hemoglobin of between 10-12 g/dL, and that patients who ...

Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine

... the PROCRIT and placebo groups. However, the hemoglobin increase was greater in the PROCRIT group. ... to an ICU for two days or more with a hemoglobin (Hb) less than 12 grams per deciliter of blood ... of PROCRIT that will gradually increase the hemoglobin (Hb) concentration to the lowest level sufficient ...

New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease

... and continuously measures SpCO and SpMet, in addition to total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), PVI, oxyhemoglobin (SpO2), pulse ... Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... (head) hemorrhage or overt sign of bleeding associated with a decrease in hemoglobin concentration of greater than 50 g/L (or hematocrit greater than 15 ... meet the requirements for TIMI major bleed, associated with a decrease in hemoglobin concentration of 30g/L to less than or equal to 50 g/L (or hematocrit 9-15 ...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... in anemia with Soliris treatment was also indicated by increased hemoglobin levels. hemoglobin levels increased from a median of 7.6 g/dL (7.9 +/- 0.3) at ...

Stroke Study Reveals a Key Target For Improving Treatment

... The level of bleeding in the brain was measured by assessing the amount of hemoglobin in the stroke-affected side of the brain. Mice that had received imatinib before tPA had 50 percent less hemoglobin than those that had not received pretreatment. This last experiment is ...

Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies

... once daily demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) versus placebo as a monotherapy and as an add-on therapy with ... 13 years. Mean age, in all studies, was between 53 and 57 years. About hemoglobin A1c (HbA1c) HbA1c is a measure of an individual's average blood sugar ...

Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers

... we are seeking for PolyHeme(R), the treatment of life-threatening hemoglobin levels when blood transfusion is required and red blood cells are not ... red blood cell substitute. It is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood ...

People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels

... subjects demonstrated an excellent favorable downward trend in their hemoglobin A1C levels. These results suggest that when administered to people with ... to cardiovascular causes such as heart attack and stroke," said Evans. hemoglobin A1C is an indicator of average blood glucose control over two to three ...

Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells

... a phase III study. The primary efficacy endpoint was the change in blood hemoglobin level from baseline to end of study, and secondary endpoints included ... achieved similar results. In the low-dose group, the increase in hemoglobin compared to placebo was not statistically significant. Treatment with ...

Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer

... RCC diagnosis to randomization, Karnofsky performance status of 60 or 70, hemoglobin less than the lower limit of normal, corrected calcium of greater than 10 ... common grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), ...

Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms

... studies, levels of C-reactive protein (CRP), a marker of inflammation, and hemoglobin levels, showed an improvement within two weeks and remained at normal ... In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin and osteoporosis and may contribute to shortening life expectancy by ...

Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks

... - MAXIMA findings in The Lancet affirm the maintenance of hemoglobin levels with less frequent dosing - NUTLEY, N.J., ... disease (CKD) patients with dosing once every two weeks and maintained hemoglobin levels in CKD patients with dosing intervals up to once monthly. In the ...

Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study

... concentration of SFP that will maintain iron balance within the target hemoglobin range, in patients undergoing hemodialysis. Secondary endpoints include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic ...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

... the primary endpoint was reached with patients benefiting from a clinically important and statistically significant (p<0.0001) increase in mean hemoglobin concentration compared with baseline after receiving velaglucerase alfa at 60 U/kg IV every other week for 12 months. Statistically significant ...

Spherix Announces Positive Phase 2 Study Results

... three separate low doses, proved to be effective for at least 6 months in reducing HbA1c, a key indicator of Type 2 diabetes that monitors glycated hemoglobin in the blood. These data, combined with the fact that Naturlose is a naturally occurring compound with no known contraindications to current Type 2 ...